Novavax published results of UK phase 3 clinical trial demonstrating high levels of COVID-19 vaccine efficacy
On Jun. 30, 2021, Novavax announced the publication of results from the final analysis of a pivotal Phase…
Gavi signed agreement with Clover Biopharmaceuticals for supply to COVAX
On Jun. 30, 2021, Gavi, the Vaccine Alliance, that it had signed an advance purchase agreement with Clover…
Fostamatinib selected for NIH ACTIV-4 COVID-19 clinical trial
On Jun. 29, 2021, Rigel Pharma announced that fostamatinib, the Company’s novel oral spleen tyrosine kinase (SYK) inhibitor,…
Adjuvant developed with NIH funding enhanced efficacy of Indiaﾒs COVID-19 vaccine
On Jun. 29, 2021, the National Institutes of Health announced that an adjuvant developed with its funding had…
Moderna provides a clinical update on neutralizing activity of COVID-19 vaccine on emerging variants
On Jun. 29, 2021, Moderna announced new results from in vitro neutralization studies of sera from individuals vaccinated…
Moderna announces Emergency Use Authorization for its COVID-19 vaccine granted by Government of India
On Jun. 29, 2021, Moderna announced that the government of India had issued a registration certificate and a…
VBI Vaccines announced initial positive phase 1 data for its eVLP vaccine candidate against COVID-19
On Jun. 29, 2021, VBI Vaccines announced positive Phase 1 data from its Phase 1/2 trial of the…
First trial participants vaccinated with Oxford COVID-19 variant vaccine
On Jun. 28, 2021, the University of Oxford in partnership with AstraZeneca began vaccinations for a new phase…
Mixed Oxford/Pfizer vaccine schedules generated robust immune response against COVID-19
On Jun. 28, 2021, researchers running the University of Oxford-led Com-COV study reported that alternating doses of the…
Biotechnology | Cartoons - Original | COVID-19 | Diagnostics | Genomics | Life Science History | Medicine | Therapeutics | U.S. Congress | Vaccine
COVID-19 PPE distribution
Cast of Characters: Jay Inslee, Governor, Washington | Gavin Newsom, Governor, California | Doug Ducey, Governor, Arizona |…
Rocheﾒs Actemra/RoActemra received FDA EUA for treatment of COVID-19 in hospitalised adults and children
On Jun. 25, 2021, Roche announced that the Food and Drug Administration (FDA) has issued an Emergency Use…
Oxford researchers identified levels of antibody protection required to prevent symptomatic COVID-19
On Jun. 24, 2021, researchers from the University of Oxford released their findings about the so-called ﾑcorrelates of…
NIH began sudy of COVID-19 vaccination during pregnancy and postpartum
On Jun. 23, 2021, the National Institutes of Health announced that an observational study had begun to evaluate…
NIH study suggested COVID-19 prevalence far exceeded early pandemic cases
On Jun. 22, 2021, National Institutes of Health researchers reported that the prevalence of COVID-19 in the U.S….
European Commission purchased additional 150 million doses of Moderna’s COVID-19 vaccine for delivery in 2022
On Jun. 22, 2021, Moderna announced that the European Commission (EC) had purchased an additional 150 million doses…
BioReference Laboratories announces first COVID-19 testing program for cruise industry
On Jun. 22, 2021, BioReference Laboratories, an OPKO Health company, announced a COVID-19 testing program for U.S. based…
Gilead’s Veklury (Remdesivir) associated with reduction in mortality rate in hospitalized patients with COVID-19
On Jun. 21, 2021, Gilead Sciences announced positive data from three retrospective studies of the real-world treatment of…
Vibativ effectively helped treat secondary bacterial infections in COVID-19 patients
On Jun. 21, 2021, Cumberland Pharma released a series of case reports describing the effectiveness of Vibativ (telavancin)…
Tonix Pharmaceuticals announced program to develop TNX-102 SL for treatment of long COVID syndrome
On Jun. 21, 2021, Tonix Pharmaceuticals announced that it planned to develop TNX-102 SL (cyclobenzaprine HCl sublingual tablets)…
CureVac provided update on phase 2b/3 trial of first-generation COVID-19 vaccine candidate, CVnCoV
On Jun. 16, 2021, CureVac announced results of the second interim analysis of its international pivotal Phase 2b/3…
Relief Therapeutics reported that NRx Pharma announced additional results from Aviptadil expanded access protocol for patients with COVID-19
On Jun. 16, 2021, RELIEF THERAPEUTICS reported that its collaboration partner, NRx Pharmaceuticals, had announced additional results from…
RECOVERY trial found Regeneron’s monoclonal antibody combination reduced deaths for hospitalised COVID-19 patients
On Jun. 16, 2021, the University of Oxford announced the Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial demonstrated…
U.S. Government purchased additional 200 million doses of Moderna’s COVID-19 vaccine
On Jun. 16, 2021, Moderna announced that the U.S. government had purchased an additional 200 million doses of…
REGEN-COV phase 3 RECOVERY trial met primary outcome, improving survival in Hospitalized COVID-19 patients
On Jun. 16, 2021, Regeneron announced positive results from the largest trial assessing any monoclonal antibody treatment in…
Data published in NEJM showed Pfizer’s Tofacitinib met primary endpoint in Brazilian study in patients with COVID-19 pneumonia
On Jun. 16, 2021, Pfizer and The Academic Research Organization (ARO) from the Hospital Israelita Albert Einstein announced…
KPWHRI announced volunteers needed for COVID-19 vaccine-booster trial
On Jun. 16, 2021, Kaiser Permanente Washington Health Research Institute (KPWHRI) announced that was recruiting volunteers in the…
Oncotelic closes COVID-19 clinical trial early
On Jun. 15, 2021, Oncotelic announced that, as of June 11, 2021, it discontinued enrollment in its OT-101…
Moderna and Magenta partner to distribute Moderna’s COVID-19 vaccine in United Arab Emirates
On Jun. 15, 2021, Moderna and Magenta Investments, an industrial conglomerate in the United Arab Emirates (UAE), announced…
Moderna submitted authorization application for its COVID-19 vaccine in adolescents in Switzerland
On Jun. 14, 2021, Moderna announced that it had submitted an authorization application to Swissmedic for use of…
Novavax COVID-19 vaccine demonstrated 90% overall efficacy and 100% protection in phase 3 trial
On Jun. 14, 2021, Novavax announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against…